I

n its latest bid to address the opioid epidemic, the Food and Drug Administration released a so-called final guidance document that is designed to help drug makers develop generic versions of abuse-deterrent painkillers.

By encouraging production of such medicines, the agency hopes to mitigate the extent to which individuals misuse opioids while simultaneously lowering prescription drug costs, a wider goal that FDA officials have adopted in recent months.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.